Drug-induced immune thrombocytopenic purpura secondary to sunitinib.
SUNITINIB (SUTENT: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration.
Trinkaus
M
M
Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON.
Trudeau
M
M
Callum
J
J